OUR UNIQUE SECTOR POSITION
Numinus is uniquely situated to facilitate the growth in the psychedelic therapy sector, with clinical research support that is crucial to bringing new drugs and therapies to the patients that need them and comprehensive training that is required to provide certified practitioners to provide care.
Numinus has established relationships with major drug developers and has been at the forefront of advancing important psychedelic treatments. Our practitioner training program is the most comprehensive available. It is accredited by major regulatory bodies in Canada and the U.S., and is provided in a blended learning format to optimize adult learning.
OUR COMPANY
Numinus Wellness Inc. is an integrated mental health company creating an ecosystem of health solutions to research, develop, and deliver safe, evidence-based, accessible psychedelic-assisted psychotherapy.
Numinus Practitioner Training
Our Practitioner Training Program is unique among those available. It is designed for both working professionals and new learners. It is interactive, modular, and based on a standard foundation that leads to distinct learning pathways for certifications in different psychedelics. It is specifically geared towards adult learners. Through our multi-course paths to practice, you’ll develop the necessary skills to provide high-quality care and become a Certified Psychedelic-Assisted Therapist. Learn more about Numinus' training opportunities here.
Cedar Clinical Research, by Numinus
Cedar Clinical Research (“CCR”) is one of the leading research facilities for late-phase 2 and phase 3 trials of psychedelics. They are the research partner of choice for leading drug development companies, including traditional pharmaceutical companies, research organizations, and the leading psychedelic drug development companies.
CCR is a valuable part of Numinus’ business. As well as building trusted relationships with drug development companies, it provides our trainers with valuable real-world experience with psychedelic medicines. It prepares us for a future when these drugs become legal. Learn more about our clinical research program here.